about
The role of levosimendan in acute heart failure complicating acute coronary syndrome: A review and expert consensus opinionGH and the cardiovascular system: an update on a topic at heartEvaluation of CXCL9 and CXCL10 as circulating biomarkers of human cardiac allograft rejection.Heart rate variability in obesity and the effect of weight loss.Bariatric surgery and long-term cardiovascular events.Feasibility of bariatric surgery as a strategy for secondary prevention in cardiovascular disease: a report from the Swedish obese subjects trial.Two year reduction in sleep apnea symptoms and associated diabetes incidence after weight loss in severe obesity.Levosimendan in acute and advanced heart failure: an appraisal of the clinical database and evaluation of its therapeutic applications.Design and rationale of the HITTS randomized controlled trial: Effect of High-intensity Interval Training in de novo Heart Transplant Recipients in Scandinavia.Continuous improvement in outcome after heart transplantation - Long-term follow-up after three decades of experience.Chronic hepatitis E infection with an emerging virus strain in a heart transplant recipient successfully treated with ribavirin: a case report.Measured and not estimated glomerular filtration rate should be used to assess renal function in heart transplant recipients.Effort-related calf pain in the obese and long-term changes after surgical obesity treatment.Can pulmonary hypertension and increased pulmonary vascular resistance be ruled in and ruled out by echocardiography?Pharmacological approaches to cardio-renal syndrome: a role for the inodilator levosimendan.Carotid artery remodelling in relation to body fat distribution, inflammation and sustained weight loss in obesity.Effects of obesity and weight loss on cardiac function and valvular performance.Are biventricular assist devices underused as a bridge to heart transplantation in patients with a high risk of postimplant right ventricular failure?The influence of body composition, fat distribution, and sustained weight loss on left ventricular mass and geometry in obesity.Impact of body composition, fat distribution and sustained weight loss on cardiac function in obesity.Incidence and remission of type 2 diabetes in relation to degree of obesity at baseline and 2 year weight change: the Swedish Obese Subjects (SOS) study.Effect of everolimus vs calcineurin inhibitors on quality of life in heart transplant recipients during a 3-year follow-up: Results of a randomized controlled trial (SCHEDULE).Successful heart transplantation from a donor with takotsubo syndrome.Quality of life 15 years after coronary artery bypass grafting.Renal function and outcome after heart transplantation.Early onset cardiomyopathy in females with Danon disease.The feasibility of left ventricular mechanical support as a bridge to cardiac recovery.Long-term outcomes of thoracic transplant recipients following conversion to everolimus with reduced calcineurin inhibitor in a multicenter, open-label, randomized trial.[Heart transplantation in AL amyloidosis].Circulating delta-like Notch ligand 1 is correlated with cardiac allograft vasculopathy and suppressed in heart transplant recipients on everolimus-based immunosuppressionEffect of Everolimus Initiation and Calcineurin Inhibitor Elimination on Cardiac Allograft Vasculopathy in De Novo Heart Transplant RecipientsDifferential Effects of Levosimendan and Dobutamine on Glomerular Filtration Rate in Patients With Heart Failure and Renal Impairment:A Randomized Double-Blind Controlled TrialEffects of bariatric surgery on cancer incidence in obese patients in Sweden (Swedish Obese Subjects Study): a prospective, controlled intervention trialLevosimendan in Acute and Advanced Heart Failure: an Expert Perspective on Posology and Therapeutic ApplicationClinical features and determinants of VO in heart transplant recipientsParvovirus B19 in Endomyocardial Biopsy of Patients With Idiopathic Dilated Cardiomyopathy: Foe or Bystander?Cardiac arrest in Wilson's disease after curative liver transplantation: a life-threatening complication of myocardial copper excess?Lower levels of the host protective IL-10 in DCM--a feature of autoimmune pathogenesis?[Better and better results of heart transplantation. Analysis of 25 years of collected experiences]Everolimus Initiation With Early Calcineurin Inhibitor Withdrawal in De Novo Heart Transplant Recipients: Three-Year Results From the Randomized SCHEDULE Study
P50
Q26745542-E3222EAA-D552-4479-9819-E45B8E1788C0Q27002329-EAE68126-2F54-4846-B852-31C33B4B169EQ33247068-E388D5DF-0380-4CF7-B782-804007B21EBAQ33859613-C6F6B34B-44B5-4046-9EF0-683CFBC4CCD8Q34030064-98D0A7D2-4149-4355-AFCA-A12C04D9077FQ34097365-2C6CD9D1-F434-445E-95C2-7F5E8975C365Q35995476-ADB2CB45-ED5C-4881-9BC9-3C0BD88E3606Q38620002-8C5546D8-64A9-40CE-9452-194B946EB490Q38726252-8F9FA5A1-B9F2-4918-B95F-B3EB75936F5BQ39192044-2912C642-538B-4957-A237-0AE3D5858CE6Q41033681-D6621F5D-7C7C-4B8D-B1C9-0274A60864C9Q41305157-203A7CBB-F253-4194-8083-1088322CDC2BQ44753944-4B0A3959-4284-4A12-9E62-BAE1CBEE16ABQ45895949-0E8BE9C8-00C3-4231-A6C7-52B75A079B80Q47154474-F8F5D46F-31F1-4F5D-B5CB-5D2EBE7CD222Q47195510-94B17D15-CEB7-40D4-9752-84DA7725D6FCQ47275205-679954AF-4EB0-47D7-90EC-2C58327F1BD7Q47354499-68C83014-FA6A-480D-B485-105356A52C8AQ47376797-81A30590-D56E-4F55-B69D-80587CB0752FQ47388442-643F1C6B-651C-453A-AF7C-05E0FE655A4DQ47390388-443CADC3-54BD-44B2-9621-EF2FACE09C4BQ47686710-B360F3C1-22C9-41F7-B303-B487CEC33BDFQ48153637-5F95DF5C-DA88-4A2D-9350-68A36177D2B1Q49109689-BF0E0CC9-6530-4975-B972-261EE7FEEE08Q50023776-29561D49-C3D8-470C-B327-7A3B3F208381Q51031115-DB004D2D-BEF0-45EC-BABB-3897A3830F03Q51079948-28BB3885-BDAA-4925-9D37-27703A5A6A13Q51533305-1F3610CF-2C39-4031-BBB4-7EA9A02252B6Q52340517-574A9C49-927F-4C2B-B817-7CB449D6C59FQ57470009-06239028-100E-4275-B454-0CFDE954519BQ57822696-A19CE135-CA82-484A-9458-EFC42B544831Q58129787-AD4C2F49-1838-41A0-BAA4-383A43836478Q58418687-87EB8D94-87EE-4804-9D32-503F1E5DACF6Q58605947-F29746B7-AC01-4592-A514-815FF04ADEAAQ58754939-214BA8A9-9F3B-4CE8-8520-70F1958F8E5EQ59354626-0D200145-65C7-4A4C-9F9F-34A588710572Q61800798-7C13D238-0A35-44F5-91C4-A0192FC6C5DFQ81946673-2E21A24C-D222-4980-A5D5-AEFAC16771EAQ82661970-90714785-980D-483A-88AC-BB7A12F3CD87Q87175147-30BF7940-40AC-43CA-AD12-042672012589
P50
description
researcher
@en
wetenschapper
@nl
name
K Karason
@en
K Karason
@nl
type
label
K Karason
@en
K Karason
@nl
prefLabel
K Karason
@en
K Karason
@nl
P106
P31
P496
0000-0002-2802-1191